Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 2/20 | 0.58 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.52 |
| ▸ | IDO1 | P14902 | 2/20 | 0.52 |
| ▸ | AGXT | P21549 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | HTR3E | A5X5Y0 | 3/20 | 0.48 |
| ▸ | HTR3B | O95264 | 3/20 | 0.48 |
| ▸ | HTR3A | P46098 | 3/20 | 0.48 |
| ▸ | HTR3D | Q70Z44 | 3/20 | 0.48 |
| ▸ | HTR3C | Q8WXA8 | 3/20 | 0.48 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.46 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5733314 | 0.98 | PNMT (0.60) | PNMTTAAR1CYP3A4IDO1AGXT | |
| SCHEMBL2436 | 0.98 | — | — | |
| SCHEMBL29353832 | 0.98 | — | — | |
| SCHEMBL11028540 | 0.95 | PNMT (0.58) | PNMTTAAR1CYP3A4IDO1AGXT | |
| SCHEMBL10876787 | 0.89 | PNMT (0.52) | PNMTTAAR1CYP3A4IDO1AGXT | |
| SCHEMBL27599728 | 0.87 | PNMT (0.50) | PNMTTAAR1CYP3A4IDO1AGXT | |
| SCHEMBL10987297 | 0.85 | TAAR1 (0.55) | PNMTTAAR1CYP3A4IDO1AGXT | |
| SCHEMBL20815578 | 0.82 | CYP3A4 (0.46) | PNMTTAAR1CYP3A4IDO1AGXT | |
| SCHEMBL25840770 | 0.81 | TSHR (0.65) | PNMTTAAR1CYP3A4IDO1AGXT | |
| SCHEMBL10879362 | 0.80 | SLC6A4 (0.46) | PNMTCYP3A4IDO1AGXTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3719018-B1 | PURINE AND DEAZAPURINE DERIVATIVES AS PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LTD (GB) | 2025-08-27 | — | — | EP | disclosed |
| EP-3421471-B1 | PURINE AND DEAZAPURINE DERIVATIVES AS PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LTD (GB) | 2021-05-26 | — | — | EP | disclosed |
| EP-3719018-A1 | PURINE AND DEAZAPURINE DERIVATIVES AS PHARMACEUTICAL COMPOUNDS | Astex Therapeutics Ltd (GB) | 2020-10-07 | — | — | EP | disclosed |
| EP-3421471-A1 | PURINE AND DEAZAPURINE DERIVATIVES AS PHARMACEUTICAL COMPOUNDS | Astex Therapeutics Limited (GB) | 2019-01-02 | — | — | EP | disclosed |
| EP-2272517-B2 | ORTHO -CONDENSED PYRIDINE AND PYRIMIDINE DERIVATIVES (E.G. PURINES) AS PROTEIN KINASES INHIBITORS | ASTEX THERAPEUTICS LTD (GB) | 2017-09-20 | — | — | EP | disclosed |
| US-9006430-B2 | Ortho-condensed pyridine and pyrimidine derivatives (e.g., purines) as protein | ASTEX THERAPEUTICS LIMITED (GB) | 2015-04-14 | — | — | US | disclosed |
| US-20140303177-A1 | ORTHO-CONDENSED PYRIDINE AND PYRIMIDINE DERIVATIVES (E.G., PURINES) AS PROTEIN KINASES INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2014-10-09 | — | — | US | disclosed |
| EP-2272517-B1 | Ortho-condensed pyridine and pyrimidine derivatives ( e.g. purines ) as protein kinases inhibitors | ASTEX THERAPEUTICS LTD (GB) | 2014-10-01 | — | — | EP | disclosed |
| US-8809336-B2 | Ortho-condensed pyridine and pyrimidine derivatives (e.g., purines) as protein kinases inhibitors | ASTEX THERAPEUTICS LIMITED (GB) | 2014-08-19 | — | — | US | disclosed |
| US-8796293-B2 | Purine and deazapurine derivatives as pharmaceutical compounds | ASTEX THERAPEUTICS LIMITED (GB) | 2014-08-05 | — | — | US | disclosed |
| US-20140107137-A1 | Ortho-Condensed Pyridine and Pyrimidine Derivatives (e.g., Purines) as Protein Kinases Inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2014-04-17 | — | — | US | disclosed |
| US-8546407-B2 | Ortho-condensed pyridine and pyrimidine derivatives (e.g., purines) as protein kinases inhibitors | ASTEX THERAPEUTICS LIMITED (GB) | 2013-10-01 | — | — | US | disclosed |
| EP-1812004-B1 | ORTHO- CONDENSED PYRIDINE AND PYRIMIDINE DERIVATIVES (E. G. PURINES) AS PROTEIN KINASES INHIBITORS | ASTEX THERAPEUTICS LTD (GB) | 2011-06-22 | — | — | EP | disclosed |
| EP-2272517-A1 | Ortho-condensed pyridine and pyrimidine derivatives ( e.g. purines ) as protein kinases inhibitors | Astex Therapeutics Limited (GB) | 2011-01-12 | — | — | EP | disclosed |
| US-20100022564-A1 | PURINE AND DEAZAPURINE DERIVATIVES AS PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2010-01-28 | — | — | US | disclosed |
| US-20090247538-A1 | Ortho-Condensed Pyridine and Pyrimidine Derivatives (e.g., Purines) as Protein Kinases Inhibitors | ASTEX THERAPEUTICS LIMITED (UK) | 2009-10-01 | — | — | US | disclosed |
| EP-2043655-A2 | PURINE AND DEAZAPURINE DERIVATIVES AS PHARMACEUTICAL COMPOUNDS | Astex Therapeutics Limited (GB) | 2009-04-08 | — | — | EP | disclosed |
| WO-2007125321-A2 | PURINE AND DEAZAPURINE DERIVATIVES AS PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2007-11-08 | — | — | WO | disclosed |
| WO-2006046024-A1 | ORTHO- CONDENSED PYRIDINE AND PYRIMIDINE DERIVATIVES (E. G. PURINES) AS PROTEIN KINASES INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2006-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140107137-A1 | Ortho-Condensed Pyridine and Pyrimidine Derivatives (e.g., Purines) as Protein Kinases Inhibitors | CDK1, CDK2, CDK3 | PNMT 1964/4885TAAR1 1155/4885CYP3A4 2639/4885 |
| US-20090247538-A1 | Ortho-Condensed Pyridine and Pyrimidine Derivatives (e.g., Purines) as Protein Kinases Inhibitors | CDK2, CDK1, OXSR1 | PNMT 2033/4885TAAR1 1131/4885CYP3A4 2629/4885 |
| US-20140303177-A1 | ORTHO-CONDENSED PYRIDINE AND PYRIMIDINE DERIVATIVES (E.G., PURINES) AS PROTEIN KINASES INHIBITORS | CDK2, CDK1, CDK3 | PNMT 1966/4885TAAR1 1192/4885CYP3A4 2676/4885 |
| US-20100022564-A1 | PURINE AND DEAZAPURINE DERIVATIVES AS PHARMACEUTICAL COMPOUNDS | TPMT, CNKSR1, PRKD3 | PNMT 2276/4885TAAR1 2190/4885CYP3A4 1384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.